TrueCAGR

Max Healthcare Institute Limited

NSE: MAXHEALTHBSE: 543220ISIN INE027H01010Face value ₹10standalone
₹1,080
+3.98% · 2026-11-20 · 52-wk ₹813–₹1,181
Source: BSE filings · Financials to FY2026 · 5 years of history · Data last updated: results filed 30 Oct 2026, prices to 20 Nov 2026 · How we calculate thisconsolidatedstandalone
Section 02 · Synthesis

What stands out?

The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.

StrengthConcernWatchContext
StrengthTalking point

Profit outpacing revenue

Profit grew 34.1% while revenue grew 19.1%, so the company kept more of each rupee of revenue as profit.

Net profit growth+34.1%Revenue growth+19.1%

Importance 63 / 95 · growth

StrengthTalking point

Compounding revenue

Revenue compounded at 20.8% a year over 4 years (₹3,931 → ₹8,373).

Importance 59 / 95 · growth

StrengthTalking point

Book value compounding

Net worth compounded at 14.4% a year over 4 years (₹6,282 → ₹10,747).

Importance 54 / 95 · financial health

Section 03 · The company

Who is this company?

Classified by the exchange under Healthcare › Healthcare › Healthcare Services › Hospital.

Market cap
₹1.05 L cr
FY2026 revenue
₹2,874 cr
FY2026 net profit
₹717 cr
Net worth
₹8,941 cr
Total debt
₹825 cr
EPS (basic)
₹7.37
Listed
NSE · BSE
Reporting
Ind-ASApr–Mar

Peer set used on this page: 3 hospital.

Section 04 · Business performance

Is the business growing?

Revenue grew 13.5% a year over 4 years, from ₹1,729 cr in FY2022 to ₹2,874 cr in FY2026. Net profit grew 21.3% a year over the same period.

Revenue & net profit — FY22 to FY26₹ crore · consolidated
₹'000 cr01223001REVENUENET PROFIT2k331FY222k694FY232k687FY243k701FY253k717FY26
RevenueNet profit
Strength

Profit grew 34.1% while revenue grew 19.1%, so the company kept more of each rupee of revenue as profit.

Rule PROFIT_FASTER_THAN_REVENUE

Revenue growth per year
+13.5%over 4 years (FY22–FY26)
Revenue growth
+7.9%vs last year
Net profit growth
+2.2%vs last year
Change in net profit since FY22
+116%

Revenue compounded at 20.8% a year over 4 years (₹3,931 → ₹8,373).

Net profit grew 34.1% year on year (FY2025 → FY2026).

Revenue grew 19.1% year on year (FY2025 → FY2026).

Section 05 · Recent activity

What changed recently?

In Q2 FY27 (Jul–Sep 2026), revenue was ₹2,569 cr (up 20.3% on the same quarter last year) and net profit ₹414 cr (down 15.6%).

Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.

Watch

Q2 FY27 net profit declined 15.6% while revenue grew 20.3% vs the same quarter last year — a gap of 36.0 percentage points.

Rule QTR_PROFIT_VS_REVENUE_GROWTH

Strength

Q2 FY27 revenue was ₹2,569 cr, up 20.3% from ₹2,135 cr in Q2 FY26 a year earlier.

Rule QTR_REVENUE_GROWTH_YOY

Concern

Q2 FY27 net profit was ₹414 cr, down 15.6% from ₹491 cr a year earlier.

Rule QTR_PROFIT_GROWTH_YOY

A. Quarterly results

Latest quarters — Q3 '25 to Q2 '27₹ crore · consolidated
₹'000 cr01223001REVENUENET PROFIT2k239Q3 '252k319Q4 '252k308Q1 '262k491Q2 '262k301Q3 '262k342Q4 '262k323Q1 '273k414Q2 '27
RevenueNet profit
QuarterRevenueYoYNet profitYoYNet margin
Q3 FY251,868+40.0%239−17.5%12.8%
Q4 FY251,910+34.2%319+26.8%16.7%
Q1 FY262,028+31.4%308+30.3%15.2%
Q2 FY262,135+25.1%491+74.3%23.0%
Q3 FY262,068+10.7%301+26.0%14.6%
Q4 FY262,143+12.2%342+7.3%16.0%
Q1 FY272,366+16.7%323+4.9%13.6%
Q2 FY272,569+20.3%414−15.6%16.1%

B. TTM snapshot

Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters

Revenue
₹9,146 crTTM
EBITDA
₹2,629 crTTM
EBIT
₹2,126 crTTM
PBT
₹1,806 crTTM
Net profit
₹1,381 crTTM

C. Corporate actions

3 Jul 2026DividendFinal Dividend - Rs. - 2.0000 — ₹2.00/share
4 Jul 2025DividendFinal Dividend - Rs. - 1.5000 — ₹1.50/share
23 Aug 2024DividendFinal Dividend - Rs. - 1.5000 — ₹1.50/share
8 Sept 2023DividendFinal Dividend - Rs. - 1.0000 — ₹1.00/share
Section 06 · Business performance

Is it becoming more profitable?

EBITDA margin was 39.1% in FY2026, against 31.6% in FY2022. ROE was 8.3% and ROCE 10.5% in FY2026.

Margins — FY22 to FY26% of revenue · consolidated
0%5%10%15%20%25%30%35%40%45%50%39.1%22.6%FY22FY23FY24FY25FY26
EBITDA marginNet margin
Strength

ROE improved from 12.1% to 14.3% year on year.

Rule ROE_IMPROVED_YOY

EBITDA margin now
39.1%
5-year range
31.6–45.0%
ROE FY2026
8.3%
ROCE FY2026
10.5%
Section 07 · Financial health

Is financial health improving?

Debt-to-equity was 0.09x in FY2026, against 0.07x in FY2022; interest coverage 24.57x. Operating cash flow was 0.70x net profit.

Net worth — FY22 to FY26₹ crore · consolidated
₹'000 cr03696kFY227kFY238kFY248kFY259kFY26
Net worth (shareholders' funds)
Strength

Net worth compounded at 14.4% a year over 4 years (₹6,282 → ₹10,747).

Rule NET_WORTH_COMPOUNDING

Operating cash flow vs net profit₹ crore · FY22–FY26
0k0k1k1k425331FY22696694FY23613687FY24598701FY25503717FY26
Operating cash flowNet profit
Total debt
₹825 cr
Operating cash flow ÷ net profit
0.70×FY2026
Free cash flow
₹153 cr
Current ratio
1.61×

Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 1.13×).

Free cash flow has been positive in 5 of the last 5 years.

Section 08 · Relative position

How does it compare with peers?

Within its 3-company Hospital peer group, it ranks 2 of 3 on return on equity and 1 of 3 on EBITDA margin. Its P/E of 76.1 compares with a peer median of 58.7.

Ranked against 3 hospital (FY2026, consolidated). No peer-relative rule fired for this company.

Revenue growth

MAXHEALTH · 1st of 3 · set median 17.3%

MAXHEALTH19.1%FORTIS17.3%APOLLOHOSP15.8%

EBITDA margin

MAXHEALTH · 1st of 3 · set median 23.4%

MAXHEALTH28.7%FORTIS23.4%APOLLOHOSP15.7%

Return on equity

MAXHEALTH · 2nd of 3 · set median 14.3%

APOLLOHOSP21.5%MAXHEALTH14.3%FORTIS11.0%

P/E ratio

MAXHEALTH · 3rd of 3 · set median 58.7×

APOLLOHOSP56.5×FORTIS58.7×MAXHEALTH76.1×
P / E
76.1×TTM to Sept 26
P / B
9.8×latest book
P / S
11.5×TTM sales
Earnings yield
1.3%TTM to Sept 26

On the trailing twelve months. Last full year: P/E 72.8× · P/S 12.3× · ROE 14.3%.

Section 09 · The stock

How has the stock performed?

The share price is down 7.6% over 1 year, up 78.7% over 3 years (21.3% a year) and up 202% over 5 years (24.7% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 8.6% below its 52-week high.

Adjusted close — 2020-09 to 2026-11₹ per share · split / bonus adjusted
0k₹1,0802020202120222023202420252026
Context

Over 4 years profit (24.3% a year) and the stock (21.3% a year) compounded at roughly the same rate — but FY2022 profit (₹605) was well below the through-cycle level (~₹1,076), so this rate is inflated by the recovery from a low base.

Rule STOCK_TRACKED_EARNINGS · recovery

Business vs stock — 5-year compound annual rate
Net profit24.3%/yrShare price21.3%/yr
1-year return
−7.6%
3-year return
+78.7%
5-year return
+202.1%
From 52-wk high
−8.6%
Section 10 · Technical data

What does the technical data say?

Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.

vs 50-day avg
Above₹942
vs 200-day avg
Above₹1,011
RSI (14)
79.2overbought
MACD histogram
21.3
From 52-wk high
−8.6%
From 52-wk low
+32.7%
30-day volatility
31.8%ann.
6-month return
+2.8%
RSI (14) · 0–10079.2 — overbought
0305070100OVERSOLDOVERBOUGHT79.2
Section 11 · Open questions

What should I investigate further?

Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.

  • Watch
    Unusual tax rate
    Effective tax rate of 13.9% (FY2026) is well below the ~25% corporate norm — a one-off tax item may be flattering or depressing reported profit.
    EFFECTIVE_TAX_UNUSUAL · conviction 37
Data coverage is complete — 5 years of financials (FY2022–FY2026), full P&L, balance sheet and cash-flow statement, sector metrics fully mapped.
Section 12 · Reference

The numbers

The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.

Income & balance sheet — ₹ crore, consolidated
MetricFY22FY23FY24FY25FY26
Revenue1,7291,9052,3412,6642,874
Total income1,8542,0492,6133,0303,176
EBITDA5467281,0331,2001,123
Profit before tax403563865947924
Net profit331694687701717
EPS (₹)3.47.27.17.27.4
Net worth6,3097,0427,6818,2898,941
Total debt449534443612825
Operating cash flow425696613598503
Free cash flow59579156345153
Key ratios — consolidated
RatioFY22FY23FY24FY25FY26
Growth
Revenue growth YoY—10.222.913.87.9
Profit growth YoY—109.7-1.02.02.2
Profitability
EBITDA margin %31.638.244.145.039.1
Net margin %17.933.926.323.122.6
Return on equity %5.210.49.38.88.3
Return on capital %6.68.611.712.610.5
Leverage & cash
Debt to equity0.070.080.060.070.09
Cash flow ÷ profit1.281.000.890.850.70
Current ratio2.363.262.011.421.61
Financials: BSE Integrated Filing inline XBRL (SEBI taxonomy), normalised to standard metric keys. Prices: end-of-day — history loaded from NSE end-of-day files, new days from the BSE bhavcopy; raw OHLC preserved; a corporate-action factor produces the adjusted series. The insight engine writes factual observations from fixed rules — it does not make recommendations. Not investment advice.